New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
20:25 EDTPFE, PFE, MNRO, MNRO, OSK, OSK, PII, PII, NUE, NUE, APD, APD, GLW, GLW, ITW, ITW, NEE, NEE, DHR, DHR, DD, DD, F, F, CMCSA, CMCSA, AKS, AKSNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Pfizer (PFE), consensus 53c; Comcast (CMCSA), consensus 68c; Ford (F), consensus 28c; DuPont (DD), consensus 55c; Danaher (DHR), consensus 95c; NextEra Energy (NEE), consensus 97c; Illinois Tool Works (ITW), consensus 91c; Corning (GLW), consensus 27c; Air Products (APD), consensus $1.33; Nucor (NUE), consensus 40c; Polaris Industries (PII), consensus $1.55; Oshkosh (OSK), consensus 33c; Monro Muffler Brake (MNRO), consensus 44c; AK Steel (AKS), consensus 2c.
News For PFE;CMCSA;F;DD;DHR;NEE;ITW;GLW;APD;NUE;PII;OSK;MNRO;AKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 9, 2014
15:03 EDTCMCSADiscovery Communications rises after CEO sees outperforming U.S. peers
Subscribe for More Information
13:45 EDTDHRDanaher to host investor and analyst meeting
Subscribe for More Information
12:22 EDTPFEPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
11:11 EDTCMCSADiscovery, Hulu announce new distribution agreement
Subscribe for More Information
10:32 EDTPFEPfizer says in talks with FDA on path forward for Mylotarg
Pfizer announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate MYLOTARG in select adult AML populations. Research was presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, December 6-9. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology, said “In particular, we are encouraged by the significant clinical evidence emerging from large randomized trials, such as AML-19 and ALFA-0701, demonstrating a positive impact of MYLOTARG when added to standard first-line treatment for patients with acute myeloid leukemia. We are engaging in discussions with the U.S. FDA and other health authorities to determine the best path forward for MYLOTARG. In addition, we plan to initiate an expanded access protocol for the therapy by the end of 2014 in the United States in patients with relapsed or refractory acute myeloid leukemia for whom there are no other treatment options.”
09:17 EDTFTeleTech to expand in China through Percepta joint venture
TeleTech Holdings (TTEC) announced plans to expand in China through Percepta, a global joint venture with Ford Motor (F). Providing service and support through all stages of the customer lifecycle, Percepta operates customer contact centers on five continents specifically for the automotive industry.
08:35 EDTGLWCorning Gorilla Glass 4 chosen for Samsung Galaxy ALPHA
Subscribe for More Information
07:44 EDTPFEAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:37 EDTFUBS to hold a conference
Subscribe for More Information
06:48 EDTCMCSAAnalysts say Netflix undermining TV ad revenue, NY Times reports
Subscribe for More Information
06:25 EDTCMCSAComcast, USA Network trialing 'Playing House' on-demand , WSJ reports
Comcast (CMCSA) is planning to make new episodes of the sitcom "Playing House" available first on its on-demand service and air them on the USA Network the following week, The Wall Street Journal reports. Reference Link
December 8, 2014
14:36 EDTCMCSATime Warner Cable CEO reports strong trends in October, November, says UBS
Subscribe for More Information
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
11:10 EDTFVolkswagen sees challenging developments continuing for rest of year
Volkswagen (VLKAY) said, “The challenging developments on markets worldwide – above all in Eastern Europe and South America – will continue for the remainder of this year. The Volkswagen Passenger Cars brand handled these challenges successfully during the course of the year, but was not entirely immune to their impact.” Other publicly traded companies in the passenger automotive space include Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), and Toyota (TM).
10:00 EDTITWOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
08:07 EDTFFord management to meet with UBS
Meeting to be held in Boston on December 8 hosted by UBS.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
07:56 EDTITWIllinois Tool Works price target raised to $110 from $95 at Stifel
Subscribe for More Information
07:53 EDTDHRDanaher price target raised to $100 from $89 at Jefferies
Jefferies raised its price target for Danaher shares to $100 ahead of the company's investor day and keeps a Buy rating on the name. It expects an initial 2015 organic growth outlook of 3% and earnings guidance of $3.95 and ex-amortization $4.40. Jefferies keeps a Buy rating on the stock.
07:07 EDTITWIllinois Tool Works upgraded to Buy from Accumulate at Global Hunter
Global Hunter upgraded Illinois Tool Works to Buy based on strong 2015 guidance, shareholder returns, and operating leverage. Price target raised to $111 from $92.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use